Crime
Palo Alto Police Search for Suspect in Charleston Gardens Burglary
Resident confronted intruder who fled the scene before police arrived.
Suspect Arrested After Attempted Robbery Near Mitchell Park
Palo Alto and Mountain View police apprehend 26-year-old San Jose man for February incident.
Palo Alto police seek suspect in downtown sexual battery
Authorities obtained surveillance footage of the alleged perpetrator who fled the scene near University Avenue
Politics
Palo Alto delays Flock camera audit after auditor recusal
City scrambles to find alternative firm to review license plate reader data policies and security
Palo Alto Approves 'Mission Critical' Objectives for Coming Year
City Council sets 42 measurable goals to carry out in the next year, including new area plans, bike master plan, and 'quiet zones' near railroad crossings.
Palo Alto struggles to reach key climate goal despite progress
City acknowledges it's unlikely to hit 80% emissions-reduction target by 2030
Science
NASA Tool to Scout Water at Moon's South Pole
Neutron Spectrometer System will ride aboard LUPEX rover to hunt for lunar ice
Fire Extinguished at Stanford's Beckman Center
Building remains closed as officials investigate cause of Sunday evening blaze.
Infamous 'Population Bomb' Author Paul Ehrlich Dies at 93
New York Times criticized for downplaying Ehrlich's failed predictions that caused harm
Health
The Counter at Santana Row Permanently Closed After Cockroach Infestation
The popular burger restaurant will not be reopening after health inspectors found multiple violations.
Guardant Health, Harris Poll Survey Shows 92% of Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered
Survey highlights strong support for expanded access to innovative blood-based colorectal cancer screening options like Guardant's FDA-approved Shield test.
Gut Bacteria Linked to Age-Related Cognitive Decline
Emerging research suggests the first signs of memory loss may originate in the gut, not the brain
Business
Novartis to acquire Excellergy for up to $2 billion
Acquisition to advance potentially first-in-class trifunctional effector cell response inhibitors for severe allergies
Excellergy to be acquired by Novartis for up to $2 billion
Acquisition to advance potentially first-in-class trifunctional effector cell response inhibitors
AppLovin Receives 'Moderate Buy' Rating from Brokerages
Analysts see potential in the mobile tech company's advertising and marketing platform
